Ranbaxy Laboratories has reported results for fourth quarter and year ended December 31, 2012.
The company has reported a net loss of Rs 616.09 crore for the quarter ended December 31, 2012 as compared to a net loss of Rs 2710.32 crore for the same quarter in the previous year. Total income of the company has decreased by 61.61% at Rs 1508.63 crore for quarter under review as compared to Rs 3930.35 crore for the quarter ended December 31, 2011.
On consolidated basis, the company has reported a net loss of Rs 492.44 crore for the quarter ended December 31, 2012 as compared to a net loss of Rs 2982.76 crore for the same quarter in the previous year. Total income of the company has decreased by 27.95% at Rs 2787.88 crore for quarter under review as compared to Rs 3869.38 crore for the quarter ended December 31, 2011.
For the fiscal 2012, the company has reported a net loss of Rs 162.33 crore for the year ended December 31, 2012 as compared to a net loss of Rs 3052.04 crore for the same in the previous year. Total income from operations went down by 16.38% to Rs 6543.14 crore from Rs 7825.19 crore in last year.
For the entire fiscal, on consolidated basis the company has reported a net profit of Rs 922.76 crore for the year ended December 31, 2012 as compared to a net loss of Rs 2899.72 crore for the same in the previous year. Total consolidated income from operations went up by 22.74% to Rs 12732.89 crore from Rs 10373.92 crore in last year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: